May 1 (Reuters) - Eli Lilly ( LLY ) on Thursday reported

first-quarter profit above Wall Street estimates, helped by

strong sales of its widely popular weight-loss and diabetes

drugs Zepbound and Mounjaro.

On an adjusted basis, the U.S. drugmaker earned $3.34 per

share for the quarter, compared with analysts' estimates of

$3.02 per share, according to LSEG data.

(Reporting by Bhanvi Satija in Bengaluru and Patrick Wingrove

in New York; Editing by Anil D'Silva)